Cargando…
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092410/ https://www.ncbi.nlm.nih.gov/pubmed/35020818 http://dx.doi.org/10.1182/bloodadvances.2021005953 |
| _version_ | 1784705134842871808 |
|---|---|
| author | Northend, Michael Wilson, William Osborne, Wendy Fox, Christopher P. Davies, Andrew J. El-Sharkawi, Dima Phillips, Elizabeth H. Sim, Hau Wui Sadullah, Shalal Shah, Nimish Peng, Ying Ying Qureshi, Iman Addada, Juanah Mora, Rocio Figueroa Phillips, Neil Kuhnl, Andrea Davies, Elizabeth Wrench, David McKay, Pamela Karpha, Indrani Cowley, Anna Karim, Richard Challenor, Sarah Singh, Vikram Burton, Cathy Auer, Rebecca Williams, Chris Cunningham, Joel Broom, Angus Arasaretnam, Anita Roddie, Claire Menne, Tobias Townsend, William |
| author_facet | Northend, Michael Wilson, William Osborne, Wendy Fox, Christopher P. Davies, Andrew J. El-Sharkawi, Dima Phillips, Elizabeth H. Sim, Hau Wui Sadullah, Shalal Shah, Nimish Peng, Ying Ying Qureshi, Iman Addada, Juanah Mora, Rocio Figueroa Phillips, Neil Kuhnl, Andrea Davies, Elizabeth Wrench, David McKay, Pamela Karpha, Indrani Cowley, Anna Karim, Richard Challenor, Sarah Singh, Vikram Burton, Cathy Auer, Rebecca Williams, Chris Cunningham, Joel Broom, Angus Arasaretnam, Anita Roddie, Claire Menne, Tobias Townsend, William |
| author_sort | Northend, Michael |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9092410 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90924102022-05-11 Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL Northend, Michael Wilson, William Osborne, Wendy Fox, Christopher P. Davies, Andrew J. El-Sharkawi, Dima Phillips, Elizabeth H. Sim, Hau Wui Sadullah, Shalal Shah, Nimish Peng, Ying Ying Qureshi, Iman Addada, Juanah Mora, Rocio Figueroa Phillips, Neil Kuhnl, Andrea Davies, Elizabeth Wrench, David McKay, Pamela Karpha, Indrani Cowley, Anna Karim, Richard Challenor, Sarah Singh, Vikram Burton, Cathy Auer, Rebecca Williams, Chris Cunningham, Joel Broom, Angus Arasaretnam, Anita Roddie, Claire Menne, Tobias Townsend, William Blood Adv Research Letter American Society of Hematology 2022-05-09 /pmc/articles/PMC9092410/ /pubmed/35020818 http://dx.doi.org/10.1182/bloodadvances.2021005953 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Research Letter Northend, Michael Wilson, William Osborne, Wendy Fox, Christopher P. Davies, Andrew J. El-Sharkawi, Dima Phillips, Elizabeth H. Sim, Hau Wui Sadullah, Shalal Shah, Nimish Peng, Ying Ying Qureshi, Iman Addada, Juanah Mora, Rocio Figueroa Phillips, Neil Kuhnl, Andrea Davies, Elizabeth Wrench, David McKay, Pamela Karpha, Indrani Cowley, Anna Karim, Richard Challenor, Sarah Singh, Vikram Burton, Cathy Auer, Rebecca Williams, Chris Cunningham, Joel Broom, Angus Arasaretnam, Anita Roddie, Claire Menne, Tobias Townsend, William Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL |
| title | Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL |
| title_full | Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL |
| title_fullStr | Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL |
| title_full_unstemmed | Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL |
| title_short | Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL |
| title_sort | results of a united kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory dlbcl |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092410/ https://www.ncbi.nlm.nih.gov/pubmed/35020818 http://dx.doi.org/10.1182/bloodadvances.2021005953 |
| work_keys_str_mv | AT northendmichael resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT wilsonwilliam resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT osbornewendy resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT foxchristopherp resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT daviesandrewj resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT elsharkawidima resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT phillipselizabethh resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT simhauwui resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT sadullahshalal resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT shahnimish resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT pengyingying resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT qureshiiman resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT addadajuanah resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT morarociofigueroa resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT phillipsneil resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT kuhnlandrea resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT davieselizabeth resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT wrenchdavid resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT mckaypamela resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT karphaindrani resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT cowleyanna resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT karimrichard resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT challenorsarah resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT singhvikram resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT burtoncathy resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT auerrebecca resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT williamschris resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT cunninghamjoel resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT broomangus resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT arasaretnamanita resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT roddieclaire resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT mennetobias resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl AT townsendwilliam resultsofaunitedkingdomrealworldstudyofpolatuzumabvedotinbendamustineandrituximabforrelapsedrefractorydlbcl |